Acalataz 100 (Acalabrutinib Capsule) 100mg

Acalataz 100 is a prescription oral capsule containing 100mg of Acalabrutinib, a highly selective small-molecule Bruton's tyrosine kinase (BTK) inhibitor. Classified as an antineoplastic agent, this medication works by blocking the specific signals that abnormal B-cells require to multiply and survive. It is utilized in targeted oncology therapies to manage specific hematological malignancies under strict medical supervision.

Strength

100mg

Pack Size

30s

Storage

Ambient

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Acalataz 100 is primarily indicated for the treatment of adult patients diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also prescribed for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior line of therapy.

Side Effects

Common side effects associated with Acalataz 100 include headaches, diarrhea, fatigue, musculoskeletal pain, bruising, and upper respiratory tract infections. Serious potential adverse reactions can include severe infections, major hemorrhages, cardiac arrhythmias such as atrial fibrillation, cytopenias, and an increased risk of developing second primary malignancies.

Precautions & Warnings

Before initiating treatment with Acalataz 100, patients must inform their healthcare provider of any history of bleeding disorders, cardiac conditions, active infections, or upcoming surgical procedures. Due to potential risks to a developing fetus, effective contraception should be used during treatment, and breastfeeding is not recommended. Regular monitoring of complete blood counts and cardiac symptoms is advised.

Avoid Interactions

Acalataz 100 can interact significantly with strong CYP3A inhibitors and inducers, which may alter the concentration of Acalabrutinib in the body. Co-administration with gastric acid-reducing agents, such as proton pump inhibitors (PPIs), H2-receptor antagonists, or antacids, can significantly decrease the absorption and efficacy of this medication. It may also increase the risk of bleeding when taken alongside anticoagulants or antiplatelet therapies.

Frequently Asked Questions

Acalataz 100 is a prescription medication indicated for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) in patients who have undergone at least one prior therapy.

Acalataz 100 contains Acalabrutinib, which acts as a Bruton's tyrosine kinase (BTK) inhibitor. By blocking this specific enzyme, the medication helps prevent the growth, survival, and spread of cancerous B-cells.

Acid-reducing medications like proton pump inhibitors (PPIs), H2 blockers, and antacids can interfere with how Acalataz 100 is absorbed. You should consult your healthcare provider for specific timing instructions or alternative options.

The most frequently reported side effects include headache, diarrhea, muscle and joint pain, fatigue, bruising, and low blood cell counts. Patients should report any persistent or severe symptoms to their doctor.

The safety of Acalataz 100 during pregnancy has not been fully established, and it may cause fetal harm. It is recommended that women of childbearing potential use effective contraception during treatment and avoid breastfeeding.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.